New Antibacterial Fillings May Combat Recurring Tooth Decay

Article

Tooth decay is among the costliest and most widespread bacterial diseases. Virulent bacteria cause the acidification of tooth enamel and dentin, which, in turn, causes secondary tooth decay.

A new study by Tel Aviv University researchers finds potent antibacterial capabilities in novel dental restoratives, or filling materials. According to the research, the resin-based composites, with the addition of antibacterial nano-assemblies, can hinder bacterial growth and viability on dental restorations, the main cause of recurrent cavities, which can eventually lead to root canal treatment and tooth extractions.

Research for the study was led by Dr. Lihi Adler-Abramovich and TAU doctoral student Lee Schnaider in collaboration with prof. Ehud Gazit, prof. Rafi Pilo, prof. Tamar Brosh, Dr. Rachel Sarig and colleagues from TAU's Maurice and Gabriela Goldschleger School of Dental Medicine and George S. Wise Faculty of Life Sciences. It was published in ACS Applied Materials & Interfaces on May 28.

"Antibiotic resistance is now one of the most pressing healthcare problems facing society, and the development of novel antimicrobial therapeutics and biomedical materials represents an urgent unmet need," says Adler-Abramovich. "When bacteria accumulate on the tooth surface, they ultimately dissolve the hard tissues of the teeth. Recurrent cavities -- also known as secondary tooth decay -- at the margins of dental restorations results from acid production by cavity-causing bacteria that reside in the restoration-tooth interface."

This disease is a major causative factor for dental restorative material failure and affects an estimated 100 million patients a year, at an estimated cost of more than $30 billion.

Historically, amalgam fillings composed of metal alloys were used for dental restorations and had some antibacterial effect. But due to the alloys' bold color, the potential toxicity of mercury and the lack of adhesion to the tooth, new restorative materials based on composite resins became the preferable choice of treatment. Unfortunately, the lack of an antimicrobial property remained a major drawback to their use.

"We've developed an enhanced material that is not only aesthetically pleasing and mechanically rigid but is also intrinsically antibacterial due to the incorporation of antibacterial nano-assemblies," Schnaider says. "Resin composite fillings that display bacterial inhibitory activity have the potential to substantially hinder the development of this widespread oral disease."

The scientists are the first to discover the potent antibacterial activity of the self-assembling building block Fmoc-pentafluoro-L-phenylalanine, which comprises both functional and structural subparts. Once the researchers established the antibacterial capabilities of this building block, they developed methods for incorporating the nano-assemblies within dental composite restoratives. Finally, they evaluated the antibacterial capabilities of composite restoratives incorporated with nanostructures as well as their biocompatibility, mechanical strength and optical properties.

"This work is a good example of the ways in which biophysical nanoscale characteristics affect the development of an enhanced biomedical material on a much larger scale," Schnaider says.

"The minimal nature of the antibacterial building block, along with its high purity, low cost, ease of embedment within resin-based materials and biocompatibility, allows for the easy scale-up of this approach toward the development of clinically available enhanced antibacterial resin composite restoratives," Dr. Adler-Abramovich says.

The researchers are now evaluating the antibacterial capabilities of additional minimal self-assembling building blocks and developing methods for their incorporation into various biomedical materials, such as wound dressings and tissue scaffolds.

Source: American Friends of Tel Aviv University

Related Videos
Patient Safety: Infection Control Today's Trending Topic for March
Infection Control Today® (ICT®) talks with John Kimsey, vice president of processing optimization and customer success for Steris.
Picture at AORN’s International Surgical Conference & Expo 2024
Infection Control Today and Contagion are collaborating for Rare Disease Month.
Rare Disease Month: An Infection Control Today® and Contagion® collaboration.
Vaccine conspiracy theory vector illustration word cloud  (Adobe Stock 460719898 by Colored Lights)
Rare Disease Month: An Infection Control Today® and Contagion® collaboration.
Infection Control Today Topic of the Month: Mental Health
Infection Control Today's topic of the month: Mental Health
Related Content